In acute myeloid leukemia (AML), Tegaserod can inhibit the translation of cyclin E2 regulated by YTHDF1, thereby affecting the proliferation and survival abilities of AML cells [114]. This evidence concerns the gene YTHDF1 and acute myeloid leukemia.